NCT03347903|Completed
Loading search results
Sponsor study identifier
observational
37
0 countries
N/A
Study Start
January 1, 2014
Actual (reported)Primary Completion
May 30, 2017
Actual (reported)Study Completion
May 30, 2017
Actual (reported)Gastroesophageal reflux disease (GERD) is involved in the development of esophageal motility disorders like Jackhammer esophagus (JE), a novel hypercontractile condition that was associated with progression to achalasia and limited outcomes following surgical anti-reflux therapy. This trial was designed to assess the prevalence and characteristics of JE in patients with typical symptoms of GERD and responsiveness to PPI therapy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 30, 2017
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2014
Actual (reported)May 30, 2017
Actual (reported)May 30, 2017
Actual (reported)November 15, 2017
Actual (reported)November 20, 2017
Actual (reported)Prevalence of Jackhammer esophagus in patients referred with symptoms of gastroesophageal reflux disease
All patients that are referred to our center with symptoms of gastroesophageal reflux disease routinely undergo high-resolution manometry. We assess how many patients are diagnosed with Jackhammer esophagus
January 2014- May 2017
Symptom perception
January 2014- May 2017
Prevalence of gastroesophageal reflux disease in patients with Jackhammer esophagus
Januar 2014- May 2017
All patients that are referred to our center undergo esophageal high-resolution manometry and ambulatory pH monitoring for screening of gastroesophageal reflux disease and motility disorders. We assess the data that are prospectively obtained. Patients do not have to undergo any interventions.
Kristo I, Schwameis K, Maschke S, Kainz A, Rieder E, Paireder M, Jomrich G, Schoppmann SF. Phenotypes of Jackhammer esophagus in patients with typical symptoms of gastroesophageal reflux disease responsive to proton pump inhibitors. Sci Rep. 2018 Jul 2;8(1):9949. doi: 10.1038/s41598-018-27756-9.
Sebastian Schoppmann, MD
Vice Chair of Department of General Surgery
37 participants (actual enrollment reported by the registry).
First Submitted
November 15, 2017
First Posted
November 20, 2017
Study Start
January 1, 2014
Actual (reported)Effect of Azithromycin on Oesophageal Hypomotility
Contact the study team to confirm eligibility.
Primary Completion
May 30, 2017
Actual (reported)Study Completion
May 30, 2017
Actual (reported)Last Updated
November 21, 2017
Record last verified: 2017-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: